The ticagrelor market has been gaining momentum in recent years due to the increasing prevalence of cardiovascular disorders across the globe. Ticagrelor is an antiplatelet medication primarily used for treating acute coronary syndromes and reducing the risk of heart attack or stroke in high-risk patients. Some of the key advantages of ticagrelor are that it is more efficient than clopidogrel in reducing cardiovascular events in acute coronary syndrome patients without significantly increasing the risk of bleeding. It selectively and reversibly binds to the P2Y12 subtype of the ADP receptor on platelets, thus inhibiting platelet activation and aggregation.

The global ticagrelor market is estimated to be valued at US$ 1481.28 Mn in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the ticagrelor market are Atlas Roofing Corporation, BASF SE, Johns Manville, Duro-Last, Inc., E. I. Du Pont De Nemours, Inc., Owens Corning, Sika AG, Standard Industries Inc., and The Dow Chemical Company. These players are focusing on developing innovative drug delivery methods and formulations to gain a competitive advantage.

The growing geriatric population which is more prone to develop cardiovascular diseases as well as increasing lifestyle-related risk factors such as obesity, smoking, and lack of physical activity are fueling the demand for Ticagrelor Market Share globally. Furthermore, advancements in drug delivery systems such as orally disintegrating tablets and injections are also contributing to market growth.

Technological advancements such as combining ticagrelor with other antiplatelets or anticoagulants in a single drug are being researched which can provide better efficacy and safety profiles. Researchers are also working on developing ticagrelor derivatives with more specific actions and lesser side effects.

Market Trends

Sustained release formulations of ticagrelor are gaining popularity as they require less frequent dosing and have better patient compliance. Manufacturers are focusing on developing various extended-release drug delivery systems such as transdermal patches.
Biosimilars of ticagrelor are also emerging as cheaper alternatives with sales expected to surge in the coming years. This will make ticagrelor more accessible to patients.

Market Opportunities

The approval of ticagrelor for new indications such as peripheral artery disease and stroke prevention will drive future growth opportunities. Expanding into untapped emerging markets of Asia Pacific and Latin America also presents lucrative prospects for manufacturers.

Impact of COVID-19 on ticagrelor market growth

The COVID-19 pandemic has impacted the ticagrelor market growth negatively in both short term and long term. During the initial lockdown period, non-essential procedures and outpatient visits were postponed which reduced the demand for ticagrelor significantly. With decline in procedures, its sales dropped abruptly. However, as COVID-19 increases risk of thrombosis and heart complications, more patients are being prescribed ticagrelor for prevention. Its use has increased among COVID-19 affected patients with co-morbidities like diabetes, hypertension etc. Further research is underway to study efficacy of ticagrelor for treating COVID-19 associated coagulation disorders.

As economic activities resume gradually, the ticagrelor market is expected to rebound owing to rise in procedures and treatment seeking behavior. However, long term impact will be seen via increased intake of unhealthy diet and lifestyle during lockdowns leading to surge in cardiovascular and thrombosis cases. This will augment the ticagrelor demand eventually. To bounce back, key strategies are increasing awareness about heart health, remote consultation for high risk groups, and investing in R&D for newer indications. Telemedicine and home delivery models can boost access amid social distancing.

Geographical regions with high ticagrelor market concentration

North America accounts for the largest share of the global ticagrelor market currently owing to high prevalence of conditions like myocardial infarction and stroke. Favourable reimbursement policies and awareness programs in the US and Canada boost patient adherence to ticagrelor. Europe is the second largest regional market due to increasing elderly population and strategic presence of leading manufacturers. Within Europe, Germany, the UK, France, Spain, and Italy contribute significantly.

Fastest growing region for ticagrelor market

Asia Pacific region is expected witness fastest growth over the forecast period for ticagrelor market propelled by improving healthcare infrastructure, rising medical tourism, and growing health insurance penetration in emerging nations like India, China and Southeast Asian countries. Initiatives to lower treatment costs along with promotion of generic drugs will augment ticagrelor uptake. Rising lifestyle diseases due to changing diets, decrease in physical activity levels and growing geriatric population present lucrative growth opportunities.

Get more insights on Ticagrelor Market